S&P 500 2,441.20 17.28
Gold$1,224.80 $5.30
Nasdaq 6,253.81 61.92
Crude Oil $60,490.00      $-1570.00
DAILY EARNINGS

Ecolab, Pfizer Net Soar; Thomson Reuters Net Declines


Author: Mukesh Buch
ticker.com
Last Update: 1:59 PM ET August 01 2017

12:00 PM New York Archer Daniels second-quarter net fell 3% to $276 million. Ecolab second-quarter net soared 15% to $297 million. HCP second-quarter net tumbled 94% to $19.3 million. Pfizer second-quarter net surged 50% to $3.1 billion. Thomson Reuters second-quarter net plunged 41% to $206 million.

Tollbooth Index increased 54.34 or 0.4% to 12,338.43.

Earnings Review

Archer Daniels Midland Company (ADM), the food processor said revenues in the second-quarter ending in June declined 4.5% from a year ago to $14.9 billion.

Net income in the quarter fell 2.8% to $276 million from $284 million and diluted earnings per share were flat at or 48 cents in the same quarter last year.

Ecolab Inc (ECL), the hygiene and energy technologies provider reported net sales in the second-quarter ending in June increased 4% from a year ago to $3.5 billion.

Net income in the quarter soared 15% to $296.6 million or $1.01 per diluted share from $258.4 million or 87 cents in the same quarter last year.

Ecolab forecasted fiscal 2017 diluted earnings per share to jump between 8% and 12% or in the range of $4.70 to $4.9.

HCP, Inc (HCP), the real estate developer said total revenues in the second-quarter ending in June plunged 14.7% from a year ago to $458.9 million.

Net income in the quarter tumbled 93.6% to $19.3 million or 4 cents per diluted share from $301.4 million or 64 cents in the same quarter last year.

The real estate developer estimated fiscal 2017 diluted earnings per share in the range of $1.18 and $1.24.

Pfizer Inc (PFE), the healthcare products maker reported revenues in the second-quarter ending in June fell 2% from a year ago to $12.9 billion.

Net income in the quarter surged 50% to $3.1 billion or 52 cents per diluted share from $2.1 billion or 34 cents in the same quarter last year.

Pfizer said sales in Enbrel declined 19.5% to $617 million and sales of Prevnar slumped 8.2% to $1.15 billion and revenues were unfavorably impacted by divestment of Hospira Infusion Systems.

Pfizer reaffirmed 2017 revenue forecast between $52 billion and $54 billion and the drug maker lifted diluted earnings per share between $2.40 and $2.45 from the earlier estimate of $2.35.

Thomson Reuters Corp (TRI), the professional financial information provider said revenues in the second-quarter ending in June were flat from a year ago to $2.8 billion.

Net income in the quarter plunged 41.1% to $206 million or 27 cents per diluted share from $350 million or 45 cents in the same quarter last year.
  1
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites. Market data: BATS Exchange. Inc